312 related articles for article (PubMed ID: 2822362)
1. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.
Polak A
Chemotherapy; 1987; 33(5):381-95. PubMed ID: 2822362
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice.
Polak A; Scholer HJ; Wall M
Chemotherapy; 1982; 28(6):461-79. PubMed ID: 6297858
[TBL] [Abstract][Full Text] [Related]
3. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
Van Cutsem J
Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy for systemic mycosis.
Polak A
Infection; 1989; 17(4):203-9. PubMed ID: 2548963
[No Abstract] [Full Text] [Related]
5. [Commonly used antifungal agents in the treatment of systemic mycoses].
Berenguer Berenguer J
Rev Clin Esp; 1995 Oct; 195 Suppl 3():58-65. PubMed ID: 9441308
[No Abstract] [Full Text] [Related]
6. Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.
Hector RF; Yee E
Antimicrob Agents Chemother; 1990 Mar; 34(3):448-54. PubMed ID: 2159257
[TBL] [Abstract][Full Text] [Related]
7. Antimycotic activity of BAY N 7133 in animal experiments.
Plempel M
J Antimicrob Chemother; 1984 May; 13(5):447-63. PubMed ID: 6330018
[TBL] [Abstract][Full Text] [Related]
8. [Systemic mycotic infections].
Meunier F
Recenti Prog Med; 1990 Jan; 81(1):18-22. PubMed ID: 2173078
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Hata K; Kimura J; Miki H; Toyosawa T; Moriyama M; Katsu K
Antimicrob Agents Chemother; 1996 Oct; 40(10):2243-7. PubMed ID: 8891122
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of pulmonary mycoses].
Schaberg T; Lode H
Dtsch Med Wochenschr; 1992 Nov; 117(45):1725-9. PubMed ID: 1330477
[No Abstract] [Full Text] [Related]
11. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.
Troke PF; Andrews RJ; Marriott MS; Richardson K
J Antimicrob Chemother; 1987 May; 19(5):663-70. PubMed ID: 3038824
[TBL] [Abstract][Full Text] [Related]
12. [In-vitro and in-vivo activity of itraconazole].
Van Cutsem J
Med Klin (Munich); 1991 Dec; 86 Suppl 1():5-8. PubMed ID: 1663204
[TBL] [Abstract][Full Text] [Related]
13. [Mycoses as opportunistic infections in AIDS patients].
Viviani MA
Med Klin (Munich); 1991 Dec; 86 Suppl 1():19-22. PubMed ID: 1663202
[TBL] [Abstract][Full Text] [Related]
14. [Antifungal combination therapy in invasive fungal infections].
Gellen-Dautremer J; Lanternier F; Dannaoui E; Lortholary O
Rev Med Interne; 2010 Jan; 31(1):72-81. PubMed ID: 19767130
[TBL] [Abstract][Full Text] [Related]
15. Combination antifungal therapy: where are we now, and where are we going?
Marr K
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 7):24-9. PubMed ID: 15651179
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo activity of antifungal agents in combination with fleroxacin, a new quinolone.
Polak A
Mycoses; 1990 Apr; 33(4):173-8. PubMed ID: 2122247
[TBL] [Abstract][Full Text] [Related]
17. Drug treatment of the systemic mycoses.
Newberry WM
Semin Drug Treat; 1972; 2(3):313-29. PubMed ID: 4617926
[No Abstract] [Full Text] [Related]
18. The in-vivo activity of an antifungal antibiotic, benanomicin A, in comparison with amphotericin B and fluconazole.
Ohtsuka K; Watanabe M; Orikasa Y; Inouye S; Uchida K; Yamaguchi H; Kondo S; Takeuchi T
J Antimicrob Chemother; 1997 Jan; 39(1):71-7. PubMed ID: 9044030
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy in systemic mycosis.
Polak A
J Chemother; 1990 Aug; 2(4):211-7. PubMed ID: 2230904
[No Abstract] [Full Text] [Related]
20. Treatment of systemic mycoses.
Abernathy RS
Medicine (Baltimore); 1973 Sep; 52(5):385-94. PubMed ID: 4725961
[No Abstract] [Full Text] [Related]
[Next] [New Search]
